Breaking News Instant updates and real-time market news.

NTLA

Intellia Therapeutics

$29.75

0.03 (0.10%)

, RGNX

Regenxbio

$33.15

1.15 (3.59%)

10:55
10/06/17
10/06
10:55
10/06/17
10:55

Alliance for Regenerative Medicine to hold a conference

Cell & Gene Meeting on the Mesa 2017 is being held in La Jolla, CA with webcasted presentations to begin on October 6 at 11 am. Webcast Link

NTLA

Intellia Therapeutics

$29.75

0.03 (0.10%)

RGNX

Regenxbio

$33.15

1.15 (3.59%)

ADVM

Adverum Biotechnologies

$3.65

-0.1 (-2.67%)

BSTG

Biostage

$0.23

-0.0756 (-24.99%)

BTX

BioTime

$2.80

0.01 (0.36%)

AST

Asterias

AET

Aetna

$162.06

0.77 (0.48%)

MESO

Mesoblast

$6.45

0.4309 (7.16%)

AGTC

Applied Genetic

$4.00

-0.1 (-2.44%)

HSGX

Histogenics

$2.18

0.13 (6.34%)

ICEL

Cellular Dynamics

BLUE

bluebird bio

$126.00

-3.4 (-2.63%)

NVS

Novartis

$85.60

-0.04 (-0.05%)

VCEL

Vericel

$5.30

-0.675 (-11.30%)

  • 10

    Oct

  • 17

    Oct

  • 06

    Nov

  • 08

    Nov

  • 17

    May

NTLA Intellia Therapeutics
$29.75

0.03 (0.10%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Intellia Therapeutics initiated with an Overweight at Barclays
Barclays initiated Intellia with an Overweight rating and $29 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
08/29/17
08/29/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JA Solar (JASO) downgraded to Sell from Hold at Axiom with analyst Gordon Johnson saying recent results suggest that Chinese module vendors are not benefiting significantly from any U.S. demand pull-in. 2. Finish Line (FINL) was downgraded to Sell from Neutral at Citi and Deutsche Bank, while being downgraded to Underperform from Neutral at Buckingham, and to Neutral from Buy at FBR Capital. 3. Intellia Therapeutics (NTLA) downgraded to Neutral from Buy at Chardan with analyst Madhu Kumar citing relative valuation. 4. Loxo Oncology (LOXO) downgraded to Market Perform from Outperform at JMP Securities with analyst Michael King saying he believes the company's platform and assets under development are now being fairly valued with the stock having risen above his $71 price target. 5. Cemex (CX) downgraded to Neutral from Buy at BofA/Merrill with analyst Carlos Peyrelongue citing lack of positive catalysts and risk of disappointment in Mexico and the U.S. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/17
CHDN
08/29/17
DOWNGRADE
CHDN
Neutral
Intellia Therapeutics downgraded to Neutral from Buy at Chardan
Chardan analyst Madhu Kumar downgraded Intellia Therapeutics to Neutral citing relative valuation and maintained a $20 price target.
07/20/17
JEFF
07/20/17
NO CHANGE
Target $36
JEFF
Buy
Intellia should be bought for long-term opportunity, says Jefferies
After touring the company's labs, Jefferies analyst Maury Raycroft recommends buying shares of Intellia Therapeutics for the company's long-term opportunity. The analyst keeps a Buy rating on the shares with a $36 price target.
RGNX Regenxbio
$33.15

1.15 (3.59%)

08/16/17
EVER
08/16/17
INITIATION
Target $25
EVER
Outperform
Regenxbio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Regenxbio with an Outperform and a $25 price target.
09/05/17
CHDN
09/05/17
NO CHANGE
Target $75
CHDN
Buy
Regenxbio price target raised to $75 from $55 at Chardan
09/19/17
SBSH
09/19/17
DOWNGRADE
Target $5.5
SBSH
Sell
Dimension Therapeutics downgraded to Sell from Neutral at Citi
Citi analyst Joel Beatty downgraded Dimension Therapeutics (DMTX) to Sell saying his base case is now the takeover proposed by Ultragenyx (RARE) will go ahead. Since Dimension s currently trading at a small premium to the $5.50 per share proposal, the analyst downgraded the stock to Sell. Beatty sees a "small but real potential" for a higher bid to come in. He believes, however, that a successful bid from Regenxbio (RGNX) would likely need to be double its original offer. The analyst raised his price target for Dimension shares to $5.50 from $3.41.
09/19/17
BARD
09/19/17
NO CHANGE
BARD
Outperform
Ultragenyx deal for Dimension would be good strategic fit, says Baird
Baird analyst Michael Ulz noted Ultragenyx (RARE) topped Regenxbio's (RGNX) bid for Dimension Therapeutics (DMTX) with a $5.50 per share offer of its own. He views the proposed acquisition of Dimension as a good strategic fit that would add a gene therapy platform and expand the early-stage pipeline. Ulz keeps an Outperform rating on Ultragenyx shares.
ADVM Adverum Biotechnologies
$3.65

-0.1 (-2.67%)

BSTG Biostage
$0.23

-0.0756 (-24.99%)

11/11/16
11/11/16
DOWNGRADE

Hold
Biostage downgraded to Hold due to financing overhang at Maxim
As previously reported, Maxim analyst Jason Kolbert downgraded Biostage to Hold from Buy given the tough financing environment for Biotech and concerns about the company's cash balance, which now stands at only $6M.
11/10/16
MAXM
11/10/16
DOWNGRADE
MAXM
Hold
Biostage downgraded to Hold from Buy at Maxim
BTX BioTime
$2.80

0.01 (0.36%)

03/30/17
RAJA
03/30/17
INITIATION
RAJA
Outperform
BioTime initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated BioTime with an Outperform rating and $6 price target.
AST Asterias

AET Aetna
$162.06

0.77 (0.48%)

10/06/17
LEER
10/06/17
NO CHANGE
LEER
Leerink convinced Amazon entering drug distribution within two years
After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.
07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
09/12/17
ARGS
09/12/17
NO CHANGE
ARGS
Aetna price target raised to $185 from $165 at Argus
Argus analyst David Toung believes that Aetna reported "strong" Q2 results. The analyst remains upbeat on the company's 2H17 outlook and keeps a Buy rating on the shares.
10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
MESO Mesoblast
$6.45

0.4309 (7.16%)

06/07/17
CANT
06/07/17
INITIATION
Target $20
CANT
Overweight
Mesoblast initiated with an Overweight at Cantor
Cantor analyst Elemer Piros initiated Mesoblast with an Overweight and a $20 price target.
08/30/17
OPCO
08/30/17
INITIATION
OPCO
Outperform
Mesoblast initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Mesoblast with an Outperform rating and $16 price target, saying it has three potential blockbuster indications for its main programs in late-stage clinical development.
06/08/17
06/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. T-Mobile (TMUS) initiated with a Buy at Drexel Hamilton. 2. Mesoblast (MESO) initiated with an Overweight at Cantor. 3. Sherwin-Williams (SHW) reinstated with a Conviction Buy at Goldman Sachs. 4. MuleSoft (MULE) initiated with a Perform at Oppenheimer. 5. Knowles (KN) initiated with a Buy at Dougherty. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/17
MAXM
04/10/17
NO CHANGE
Target $14
MAXM
Buy
Mesoblast HF trial chance of success not fully relected in shares, says Maxim
After Mesoblast announced that the Independent Data Monitoring Committee for its Phase 3 trial of its allogeneic mesenchymal precursor cell product candidate found that an interim futility analysis was successful and that the trial can continue, Maxim analyst Jason Kolbert said the design of the trial is robust and "in many ways superior" to prior heart failure trials attempted by others. The analyst sees the chances of success for Mesoblast's HF trial as "substantially greater" than represented by the stock's current valuation and keeps a Buy rating and $14 price target on the shares.
AGTC Applied Genetic
$4.00

-0.1 (-2.44%)

09/14/17
BMOC
09/14/17
NO CHANGE
BMOC
Applied Genetic price target lowered to $7 from $14 at BMO Capital
BMO Capital analyst Matthew Luchini cut his price target on Applied Genetic as he lowered the chances of success of its lead XLRS program to 40% from 70%. He lowered the program's chance of success due to what he sees as lack of impact on patients treated in the dose escalation portion of a trial. However, the analyst believes that new Phase I/II data due to be reported in late 2017 or early 2018 could "help unlock a roughly $750M peak sales opportunity." He keeps an Outperform rating on the shares.
09/14/17
CANT
09/14/17
NO CHANGE
Target $9
CANT
Neutral
Applied Genetic price target lowered to $9 from $15 at Cantor
Cantor Fitzgerald analyst Mara Goldstein lowered her price target for Applied Genetic Technologies to $9 and keeps a Neutral rating on the name following the company's Q4 results and business update. The analyst cites the slow clinical progression of the company's trials and the revelation that the XLRS trial may need additional patients and time to identify therapeutic activity for the lowered target. She sees a "lack of actionable clinical data" in the near-term.
03/15/17
RODM
03/15/17
INITIATION
Target $16
RODM
Buy
Applied Genetic initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Applied Genetic Technologies with a Buy rating and $16 price target. The analyst calls the company a leader in adeno-associated virus development.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $8
HCWC
Buy
H.C. Wainwright halves Applied Genetic target on timeline pushouts
H.C. Wainwright analyst Joseph Pantginis halved his price target for Applied Genetic Technologies to $8 from $16 following the company's 2017 results. Today's XLRS update should increase frustration because the timeline has been pushed out to approximately mid-2018 for the potential data, Pantginis tells investors in a research note. The analyst pushed out his projected launch year for XLRS and ACHM-B3 from 2022 to 2023. He reiterates a Buy rating on Applied Genetic.
HSGX Histogenics
$2.18

0.13 (6.34%)

12/19/16
HCWC
12/19/16
INITIATION
Target $3.5
HCWC
Buy
Histogenics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Histogenics with a Buy rating and $3.50 price target.
ICEL Cellular Dynamics

BLUE bluebird bio
$126.00

-3.4 (-2.63%)

10/02/17
10/02/17
DOWNGRADE
Target $105

Underweight
bluebird bio downgraded to Underweight on sickle cell risk at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded bluebird bio (BLUE) to Underweight from Equal Weight, as he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. The analyst, who notes the stock is up over 40% since Gilead's (GILD) acquisition of Kite Pharma (KITE) set off excitement about the CAR-T space that blue is also in, doesn't believe the ASH data will demonstrate the improvement in hemoglobin production necessary to increase confidence in sickle cell genetherapy, he tells investors. Harrison keeps a $105 price target on bluebird bio shares.
10/06/17
GSCO
10/06/17
INITIATION
Target $186
GSCO
Conviction Buy
bluebird bio reinstated with a Conviction Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on bluebird with a Conviction Buy and $186 price target due to its leading position in the highly innovative gene and dell therapy fields, with a focus on curative/corrective one-time treatment.
10/03/17
WELS
10/03/17
NO CHANGE
WELS
Outperform
bluebird bio should be bought on weakness, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on shares of bluebird bio and recommends buying on weakness, following a call with management and what he believes to be flawed competitor analysis related to the companies LentiGlobin gene therapy program for Sickle Cell Disease. With concerns raised regarding correlation between ex vivo drug product vector copy number and in vivo peripheral vector copy number, the analyst believes that pooling of small patient numbers, from different studies, not consistently exposed to the same gene therapy product or transplant protocol, provides inadequate framework for correlation analysis and conclusion on prospects for clinical success in Sickle Cell Disease. Importantly, Birchenough argues that at the current bluebird bio share price of $120/share, only $16/share is attributable to Sickle Cell Disease, with an implied likelihood of success of only 10%, and that base value of $104/share can be supported by BCMA CAR-T, LentiGlobin for Beta Thalassemia, and gene therapy for adrenoleukodystrophy.
10/02/17
10/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying North American beverage trends continue to deteriorate and Pepsi's likely need for reinvestment should "cap the stock" over the next 12 months. 2. Western Digital (WDC) downgraded to Neutral from Outperform at Baird with analyst Tristan Gerra saying he believes the potential outcomes from the company's ongoing litigation with Toshiba (TOSYY) "range from neutral to significantly negative" and the ongoing fight will cap the stock's valuation in the near-term. 3. Uniti Group (UNIT) downgraded to Neutral from Overweight at JPMorgan with analyst Philip Cusick saying the "theme of Windstream's (WIN) distress continues to increase in volume." 4. Parker-Hannifin (PH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Nigel Coe saying he sees a more balanced risk-reward following the stock's strong outperformance since the election. 5. bluebird bio (BLUE) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Matthew Harrison saying he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NVS Novartis
$85.60

-0.04 (-0.05%)

08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/03/17
JANY
10/03/17
NO CHANGE
Target $12
JANY
Buy
Cryoport price target raised to $12 from $10 at Janney Capital
Janney Capital analyst Paul Knight raised his revenue and earnings estimates for Cryoport (CYRX) to account for previous announcements that it will be the supplier of logistics and shipping solutions for Novartis (NVS) and Kite (KITE) if their regenerative medicines are approved. The analyst, who raised his fair value estimate on Cryoport shares to $12 from $10, also noted that the company is involved in 172 additional clinical trials. He keeps a Buy rating on Cryoport shares.
VCEL Vericel
$5.30

-0.675 (-11.30%)

12/22/16
PIPR
12/22/16
INITIATION
Target $6
PIPR
Overweight
Vericel initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated Vericel with an Overweight rating and $6 price target, saying he sees the company's recently approved Matrix-induced Autologous Chondrocyte Implant to drive cartilage repair growth. Tenthoff predicts combined knee ACI sales growth of 23.3% to $44.5M in 2017 and then MACI growth of 21% to $54M in 2018.
06/20/17
BTIG
06/20/17
INITIATION
BTIG
Buy
Vericel initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started Vericel with a Buy rating and $6 price target, citing its first mover advantage in advanced cartilage repair and a simplified technique for surgeons.
10/05/17
10/05/17
NO CHANGE

Piper keeps Vericel at Overweight, says ixmyelocel-T not in model
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $7 price target on Vericel after the company announced it met with FDA and will be required to conduct an additional study to support a BLA filling for ixmyelocel-T in ischemic dilated cardiomyopathy. Tenthoff noted that Piper did not currently value ixmyelocel-T, and that Vericel did not intend to conduct any additional studies without a partner.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.